CD274 and non-small cell lung carcinoma: The NCCN guidelines recommend PD-1/PD-L1 inhibitors as the first-line treatment for advanced NSCLC patients with a PD-L1+ cell rate ≥ 1%; nonetheless, some studies have shown that PD-L1 has limitations in predicting the efficacy of immunotherapy.